Skip to content

An open clinical trial of an adapted inpatient addiction treatment with group Schema Therapy and milieu therapy

Effectiveness of an adapted inpatient treatment with Schema Therapy and milieu therapy for SUD and comorbid PD in a religious setting (A baseline controlled case series design)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON22685
Enrollment
12
Registered
2019-11-28
Start date
2019-12-02
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Personality disorder, substance use disorder

Interventions

A therapeutic approach, including a group Schema Therapy as well as SafePath (a milieu-form of ST) aimed at substance use disorder and personality disorder provided in a clinical setting during 12 wee

Sponsors

No sponsors
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion criteria are that patients have an indication for treatment in an inpatient setting for SUD (substance use disorder) at the 4life clinic at the Hoop ggz, following the Dutch guidelines (De Beer & Van de Glind, 2009). Patients have a diagnosis of DSM-5 SUD and have minimally five PD traits (this is seen as clinically significant for PD (Verheul, Bartak, & Widiger, 2007)), age 18-65 years, with an indication of at least a normal intelligence based on a completed primary and secondary education and clinical impression, and a willingness to participate in the study confirmed by a signed informed consent.

Exclusion criteria

Exclusion criteria: Exclusion criteria are an severe autism spectrum disorder, schizophrenia or other psychotic disorders, and the presence of significant risk for suicide based on psychiatric evaluation. Other exclusion criteria are the current use of heroin, methadone or another heroin replacement, acute delirium symptoms, or have otherwise specific medical needs. These clients are refered to a more medical oriented inpatient detoxification. Further, we exclude patients whose waiting list times are less than two weeks, because that allows insufficient time to gather three necessary baseline observations.

Design outcomes

Primary

MeasureTime frame
Dysfunctional core belief strength (visual analog scale 0-100)

Secondary

MeasureTime frame
Craving for drugs (PACS, also adapted for different substances); global impairment (OQ-45); QGR-S (visual analog scale); SCID-5-PV; SMI; YSQ (35 items); PID-5-SF

Contacts

Public ContactTheodoor Kraker

de Hoop GGz

t.dekraker@dehoop.org0786111111

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)